S1424
Interdisciplinary - Health economics & health services research
ESTRO 2026
treatment (n=4,998, 26.3%). Only 1,719 (9.0%) patients received NAC before RC or RRT. After adjusting for case-mix, females and individuals from deprived areas with NM-MIBC were less likely to receive any radical treatment, with an absolute difference of -5.52 percentage points (pp.), (95%CI: -6.82;-4.21) and -4.61 pp. (95%CI -6.51;-2.71) compared to males and the least deprived group respectively. More specifically, both females and individuals from deprived areas were less likely to receive RC, with and without NAC (Figure 1). However, we only observed reduced radiotherapy receipt after NAC among females (1.88pp. 95%CI -3.19;-0.57) but not individuals residing in deprived areas.
B. Bachtiary, L. Grawehr, F. Grillo Ruggieri, U. Held, and D. C. Weber: Financial Toxicity in Swiss Cancer Patients Treated with Proton Therapy: An Observational Cross- Sectional Study on Self-Reported Outcome. Cancers (Basel) 2023 Vol. 15 Issue 23 Keywords: Proton Therapy, Financial Stress
Digital Poster 3934
Who gets curative treatment for non-metastatic bladder cancer? A national population-based study evaluating sociodemographic inequalities in England Eva Kagenaar 1 , David G Lugo-Palacios 1 , Hannah L Bromley 2,3 , Ajay Aggarwal 4,1 , Stephen O'Neill 1 , Bernard Rachet 1 , Sayana Lee 1 , Jo Cresswell 5 , Ananya Choudhury 2,3 , Richard Grieve 1 1 Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom. 2 Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 4 Department of Oncology, Guy's & St Thomas' NHS Trust, London, United Kingdom. 5 Department of Surgery, South Tees NHS Trust, Middlesbrough, United Kingdom Purpose/Objective: Neoadjuvant chemotherapy (NAC) followed by curative treatment – radical cystectomy (RC) or radical radiotherapy (RRT) – is the recommended treatment for non-metastatic muscle invasive bladder cancer (NM-MIBC) (1). However, there is variation in curative- intent treatment uptake across England. This study aimed to evaluate the sociodemographic factors associated with surgery or radiotherapy, for NM-MIBC in England during 2012-2022. Material/Methods: All patients diagnosed with NM-MIBC (T2-T4aN0M0) in England during 2012-2022 were identified from the National Cancer Registry. Data were linked to Hospital Episode Statistics, National Radiotherapy Dataset and the Systemic Anti-Cancer Therapy Dataset to obtain clinical and socio-demographic characteristics and treatment receipt. Multinomial logistic regression was used to predict the percentage who received each treatment (versus no treatment) adjusted for age, sex, ethnicity, area-level income deprivation, tumour stage, histology, comorbidity, and frailty score. Results: NM-MIBC diagnoses were registered in 19,002 patients (median age 77 years, 72.3% male). Just over half received curative treatment, RC or RRT +/- NAC (n=9,556, 50.3%) (Table 1). Approximately one in four patients had palliative therapy (n=4,448, 23.4%) or no
Conclusion: Radical treatment for NM-MIBC in England remains suboptimal, with limited uptake of NAC prior to any radical treatment despite recommendation. Females and those who live in more deprived areas are less likely to receive radical treatment than males and
Made with FlippingBook - Share PDF online